We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Leaflet explaining how diabetic eye screening (DES) works, to help healthcare professionals discuss screening and results with their patients.
For the first time in the UK, obese patients and people who are overweight with weight-related health problems could now have access to Mounjaro, currently used for Type 2 diabetes, to help manage their weight and support weight loss.
This document describes the diabetic eye screening (DES) pathway.
An advisory panel working together with the DVLA providing expert advice with the aim of improving road safety.
This document sets out an overview of the operational pathways in the NHS Diabetic Eye Screening (DES) programme.
Guidance for when a person with diabetes chooses to be screened by a different diabetic eye screening (DES) service from the one their GP is linked to.
Information explaining diabetic retinopathy, a disease screened for by the NHS diabetic eye screening (DES) programme.
How to manage individuals not included on an eye screening service register of people with diabetes.
Information for people referred from diabetic eye screening (DES) because they need regular monitoring or treatment.
Information explaining the NHS diabetic eye screening programme.
Local NHS diabetic eye screening (DES) providers must use these letters to invite people for screening and inform them of their results.
Decreased vitamin B12 levels, or vitamin B12 deficiency, is now considered to be a common side effect in patients on metformin treatment, especially in those receiving a higher dose or longer treatment duration and in those with existing risk factors....
The authorisation holder for dapagliflozin has withdrawn the indication for type 1 diabetes mellitus. The removal of the type 1 diabetes indication is not due to any new safety concerns and the other indications of dapagliflozin are unchanged.
Innovate UK-supported life science company Phynova finds further evidence that its plant-based food ingredient promotes healthy blood sugar.
New data reveals overall number of amputations increasing with white males having the highest rate.
New data from PHE reveals 3.8 million people in England aged over 16 had diabetes in 2015, around 9% of the adult population.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey.